New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 15, 2014
07:35 EDTNLNKNewLink Genetics price target raised to $35 from $23 at Canaccord
Canaccord is more optimistic that the P3 IMPRESS trial of HyperAcute Pancreas in resected pancreatic cancer could meet its primary endpoint of an improvement in overall survival vs. placebo following a management meeting. Shares are Buy rated.
News For NLNK From The Last 14 Days
Check below for free stories on NLNK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2014
12:09 EDTNLNKNewLink Genetics contracts for manufacture of Ebola vaccine candidate
NewLink Genetics disclosed in a regulatory filing that the company has contracted for the manufacture of its Ebola vaccine candidate, rVSV-ZEBOV-GP. "The company currently holds sufficient quantities of the vaccine candidate to begin preclinical trials, and the third-party manufacturing capacity will allow the company to augment its current supply of the vaccine candidate," NewLink stated.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use